The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders

References

• Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation113(7), e166–e286 (2006).
   PubMedGoogle Scholar
• Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA293(17), 2126–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol.45(2), 246–251 (2005).
   PubMed Web of Science ®Google Scholar
• Bernlochner I, Steinhubl S, Braun S et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb. Haemost.104(6), 1193–1200 (2010).
   PubMed Web of Science ®Google Scholar
• Geisler T, Anders N, Paterok M et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care30(2), 372–374 (2007).
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis195(1), e217–e223 (2007).
   PubMedGoogle Scholar
• Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost.101(4), 714–719 (2009).
   PubMed Web of Science ®Google Scholar
• Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am. J. Cardiol.100(2), 203–205 (2007).
   PubMed Web of Science ®Google Scholar
• Geisler T, Grass D, Bigalke B et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J. Thromb. Haemost.6(1), 54–61 (2008).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet376(9749), 1312–1319 (2010).
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360(4), 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA304(16), 1821–1830 (2010).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Stegherr J, Latz W et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur. Heart J.30(8), 916–922 (2009).
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA303(8), 754–762 (2010).
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol.48(9), 1742–1750 (2006).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol.53(10), 849–856 (2009).
   PubMed Web of Science ®Google Scholar
• Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol.49(24), 2312–2317 (2007).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Antonino MJ, Bliden KP et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets19(8), 595–604 (2008).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Braun S et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb. Haemost.103(1), 151–159 (2010).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Schulz S, Braun S et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J. Thromb. Haemost.8(2), 250–256 (2010).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J. Am. Coll. Cardiol.56(4), 317–318 (2010).
   PubMed Web of Science ®Google Scholar
• Mehran R, Pocock SJ, Stone GW et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur. Heart J.30(12), 1457–1466 (2009).
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Berger PB, Mehilli J et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J. Am. Coll. Cardiol.51(7), 690–697 (2008).
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol.56(12), 919–933 (2010).
   PubMed Web of Science ®Google Scholar
• Born GV, Cross MJ. Effect of adenosine diphosphate on the concentration of platelets in circulating blood. Nature197, 974–976 (1963).
   PubMed Web of Science ®Google Scholar
• Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv.59(3), 295–302 (2003).
   PubMed Web of Science ®Google Scholar
• Bonello L, Paganelli F, Arpin-Bornet M et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost.5(8), 1630–1636 (2007).
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Quilici J et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost.98(4), 838–843 (2007).
   PubMed Web of Science ®Google Scholar
• Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb. Haemost.103(6), 1210–1217 (2010).
   PubMed Web of Science ®Google Scholar
• Taubert D, von Beckerath N, Grimberg G et al. Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther.80(5), 486–501 (2006).
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost.84(5), 891–896 (2000).
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos.38(1), 92–99 (2010).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation107(23), 2908–2913 (2003).
   PubMed Web of Science ®Google Scholar
• Serebruany V, Rao SV, Silva MA et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur. Heart J.31(2), 227–235 (2010).
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation109(25), 3171–3175 (2004).
   PubMed Web of Science ®Google Scholar
• Ibrahim K, Hass N, Kolschmann S, Strasser RH, Braun-Dullaeus RC. Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? Clin. Res. Cardiol.97(11), 797–800 (2008).
   Google Scholar
• Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin. Drug Metab. Toxicol.5(8), 989–1004 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA302(8), 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Gebhard D, Koch W et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J. Thromb. Haemost.8(8), 1685–1693 (2010).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation121(4), 512–518 (2010).
   PubMed Web of Science ®Google Scholar
• Lau WC, Gurbel PA, Watkins PB et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation109(2), 166–171 (2004).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation121(4), 481–483 (2010).
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet373(9660), 309–317 (2009).
   PubMed Web of Science ®Google Scholar
• Giusti B, Gori AM, Marcucci R et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics17(12), 1057–1064 (2007).
   PubMed Web of Science ®Google Scholar
• Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol.51(20), 1925–1934 (2008).
   PubMed Web of Science ®Google Scholar
• Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol.56(2), 134–143 (2010).
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet376(9749), 1320–1328 (2010).
   PubMed Web of Science ®Google Scholar
• Pare G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med.363(18), 1704–1714 (2010).
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med.339(23), 1665–1671 (1998).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther.79(1), 103–113 (2006).
   PubMed Web of Science ®Google Scholar
• Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol.69(3), 222–230 (2010).
   PubMed Web of Science ®Google Scholar
• Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics10(1), 43–49 (2009).
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J. Thromb. Haemost.7(8), 1409–1141 (2009).
   PubMed Web of Science ®Google Scholar
• Geisler T, Schaeffeler E, Dippon J et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics9(9), 1251–1259 (2008).
   PubMed Web of Science ®Google Scholar
• Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos.31(1), 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Suh JW, Koo BK, Zhang SY et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ174(12), 1715–1722 (2006).
   PubMed Web of Science ®Google Scholar
• Smith SM, Judge HM, Peters G et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets17(4), 250–258 (2006).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul. Fibrinolysis15(1), 89–93 (2004).
   PubMed Web of Science ®Google Scholar
• Fontana P, Dupont A, Gandrille S et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation108(8), 989–995 (2003).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb.120(6), 893–899 (2007).
   PubMed Web of Science ®Google Scholar
• Lev EI, Patel RT, Guthikonda S et al. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb.119(3), 355–360 (2007).
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schomig E, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med.17(1), 110–116 (2010).
   PubMedGoogle Scholar
• Sibbing D, Koch W, Massberg S et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur. Heart J.32(13), 1605–1613 (2011).
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol.51(3), 256–260 (2008).
   PubMed Web of Science ®Google Scholar
• Siller-Matula J, Spiel A, Lang I et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J.157(1), e1-e5 (2009).
   Google Scholar
• Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J. Am. Coll. Cardiol.54(13), 1149–1153 (2009).
   PubMed Web of Science ®Google Scholar
• Dunn SP, Macaulay TE, Brennan DM et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation118, S815 (2008).
   Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L et al. Proton pump inhibitors may attenuate the benefits of clopidogrel among ACS patients: Empirical evidence from 3,311 ACS patients. Circulation118, S_1165 (2008).
   Google Scholar
• Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA301(9), 937–944 (2009).
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ180(7), 713–718 (2009).
   PubMed Web of Science ®Google Scholar
• Kreutz RP, Stanek EJ, Aubert R et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy30(8), 787–796 (2010).
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet374(9694), 989–997 (2009).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med.363(20), 1909–1917 (2010).
   PubMed Web of Science ®Google Scholar
• Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur. J. Clin. Pharmacol.55(11–12), 843–852 (2000).
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit.29(6), 687–710 (2007).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins), the importance of CYP enzymes, transporters and pharmacogenetics. Curr. Opin. Investig. Drugs11(3), 323–332 (2010).
   PubMed Web of Science ®Google Scholar
• Park JE, Kim KB, Bae SK et al. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica38(9), 1240–1251 (2008).
   PubMed Web of Science ®Google Scholar
• Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb. Haemost.100(6), 1052–1057 (2008).
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost.5(12), 2429–2436 (2007).
   PubMed Web of Science ®Google Scholar
• Ufer M, Svensson JO, Krausz KW et al. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur. J. Clin. Pharmacol.60(3), 173–182 (2004).
   PubMed Web of Science ®Google Scholar
• Lau WC, Waskell LA, Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation107(1), 32–37 (2003).
   PubMed Web of Science ®Google Scholar
• Saw J, Steinhubl SR, Berger PB et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. 108(8), 921–924 (2003).
   Google Scholar
• Gorchakova O, von Beckerath N, Gawaz M et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur. Heart J.25(21), 1898–1902 (2004).
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart96(3), 186–189 (2010).
   PubMed Web of Science ®Google Scholar
• Harmsze AM, Robijns K, van Werkum JW et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb. Haemost.103(5), 920–925 (2010).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J. Am. Coll. Cardiol.52(19), 1557–1563 (2008).
   PubMed Web of Science ®Google Scholar
• Sarafoff N, Neumann L, Morath T et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am. Heart J.161(3), 605–610 (2011).
   Google Scholar
• Sarafoff N, Ndrepepa G, Mehilli J et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J. Intern. Med.264(5), 472–480 (2008).
   PubMed Web of Science ®Google Scholar
• Sibbing D, von Beckerath N, Morath T et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur. Heart J.31(10), 1205–1211 (2010).
   PubMed Web of Science ®Google Scholar
• Rehmel JL, Eckstein JA, Farid NA et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab. Dispos.34(4), 600–607 (2006).
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol.50(2), 126–142 (2010).
   PubMed Web of Science ®Google Scholar
• Varenhorst C, James S, Erlinge D et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur. Heart J.30(14), 1744–1752 (2009).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J.29(1), 21–30 (2008).
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J.153(1), 66 e9–e16 (2007).
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Matsushima N, Asai F et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br. J. Clin. Pharmacol.63(4), 421–430 (2007).
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J.27(10), 1166–1173 (2006).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation116(25), 2923–2932 (2007).
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol.51(14), 1404–1411 (2008).
   PubMed Web of Science ®Google Scholar
• Kastrati A, von Beckerath N, Joost A et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation110(14), 1916–1919 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7), a randomised factorial trial. Lancet376(9748), 1233–1243 (2010).
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38), double-blind, randomised controlled trial. Lancet373(9665), 723–731 (2009).
   PubMed Web of Science ®Google Scholar
• Osmancik P, Jirmar R, Hulikova K et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc. Interv.75(2), 158–566 (2009).
   Google Scholar
• Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J.27(9), 1038–1047 (2006).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol.50(19), 1844–1851 (2007).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation120(25), 2577–2585 (2009).
   PubMed Web of Science ®Google Scholar
• Storey RF, Bliden KP, Patil SB et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J. Am. Coll. Cardiol.56(3), 185–193 (2010).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J.151(3), 689 e1-e10 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin. Ther.24(5), 752–765 (2002).
   PubMed Web of Science ®Google Scholar
• Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets12(7), 443–447 (2001).
   PubMed Web of Science ®Google Scholar
• Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost.85(3), 401–407 (2001).
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med.361(24), 2318–2329 (2009).
   PubMed Web of Science ®Google Scholar
• Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost.6(7), 1153–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Oh JJ, Oestreich JH et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb.121(4), 527–534 (2008).
   PubMed Web of Science ®Google Scholar
• Berger JS, Roe MT, Gibson CM et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid Reversal of Platelet Thrombosis with Intravenous Elinogrel before PCI to Optimize Reperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial. Am. Heart J.158(6), 998–1004 (2009).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Antonino MJ et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J. Thromb. Haemost.8(1), 43–53 (2010).
   PubMedGoogle Scholar
• Leonardi S, Rao SV, Harrington RA et al. Rationale and Design of the Randomized, Double-Blind Trial Testing Intravenous and Oral Administration of Elinogrel, a Selective and Reversible P2Y(12)-receptor inhibitor, versus Clopidogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Interventions Eatients (INNOVATE-PCI). Am. Heart J.160(1), 65–72 (2010).
   PubMed Web of Science ®Google Scholar
• Davi G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med.357(24), 2482–2494 (2007).
   PubMed Web of Science ®Google Scholar
• Goto S, Yamaguchi T, Ikeda Y et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J. Atheroscler. Thromb.17(2), 156–164 (2010).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb. Haemost.102(1), 111–119 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J.31(1), 17–28 (2010).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol.46(10), 1820–1826 (2005).
   PubMed Web of Science ®Google Scholar
• Price MJ, Endemann S, Gollapudi RR et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J.29(8), 992–1000 (2008).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Christ G, Lang IM et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J. Thromb. Haemost.8(2), 351–359 (2010).
   PubMed Web of Science ®Google Scholar
• Poston R, Gu J, Manchio J et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur. J. Cardiothorac. Surg.27(4), 584–591 (2005).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Cayla G, Frere C et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention5(3), 325–329 (2009).
   PubMed Web of Science ®Google Scholar
• Mokhtar OA, Lemesle G, Armero S et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb. Res.126(2), e147–e149 (2010).
   Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med.361(24), 2330–2341 (2009).
   PubMed Web of Science ®Google Scholar
• Aleil B, Rochoux G, Monassier JP, Cazenave JP, Gachet C. Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases. J. Thromb. Haemost.5(4), 879–881 (2007).
   Google Scholar
• Pena A, Collet JP, Hulot JS et al. Can we override clopidogrel resistance? Circulation119(21), 2854–2857 (2009).
   PubMed Web of Science ®Google Scholar
• Szymezak J, Moreau C, Loriot MA et al. High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment. Thromb. Res.128(1), 92–95 (2011).
   Google Scholar
• Bonello L, Camoin-Jau L, Armero S et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol.103(1), 5–10 (2009).
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA305(11), 1097–1105 (2011).
   PubMed Web of Science ®Google Scholar
• Blindt R, Stellbrink K, de Taeye A et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb. Haemost.98(6), 1329–1334 (2007).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost.4(3), 542–549 (2006).
   PubMed Web of Science ®Google Scholar
• Eshtehardi P, Windecker S, Cook S et al. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am. Heart J.159(5), 891–898 e1 (2010).
   PubMed Web of Science ®Google Scholar
• Geisler T, Zurn C, Simonenko R et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur. Heart J.31(1), 59–66 (2010).
   PubMed Web of Science ®Google Scholar
• Geisler T, Langer H, Wydymus M et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart J.27(20), 2420–2425 (2006).
   PubMed Web of Science ®Google Scholar
• Gori AM, Marcucci R, Migliorini A et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J. Am. Coll. Cardiol.52(9), 734–739 (2008).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Samara W et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J. Am. Coll. Cardiol.46(10), 1827–1832 (2005).
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation119(2), 237–242 (2009).
   PubMed Web of Science ®Google Scholar
• Migliorini A, Valenti R, Marcucci R et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation120(22), 2214–2221 (2009).
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Mangiacapra F et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol.52(14), 1128–1133 (2008).
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Zhou YJ, Liu YY et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb. Res.124(1), 46–51 (2009).
   Google Scholar
• Chen L, Bracey AW, Radovancevic R et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg.128(3), 425–431 (2004).
   PubMed Web of Science ®Google Scholar
• Michelson AD, Frelinger AL 3rd, Braunwald E et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J.30(14), 1753–1763 (2009).
   PubMed Web of Science ®Google Scholar
• Rahe-Meyer N, Winterhalter M, Boden A et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol. Scand.53(2), 168–175 (2009).
   PubMed Web of Science ®Google Scholar